| 2021 |
Everts-Graber J, Reichenbach S, Gahl B, Ziswiler H, Studer U, Lehmann T. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone. March 2021;144:115830. |
6 |
3 |
| 2022 |
Everts-Graber J, Reichenbach S, Gahl B, Häuselmann H, Ziswiler H-R, Studer U, Lehmann T. Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting. Bone. October 2022;163:116498. |
1 |
1 |
| 2020 |
Everts‐Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T. A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res. July 2020;35(7):1207-1215. |
10 |
8 |
| 2022 |
Everts-Graber J, Lehmann D, Burkard J-P, Schaller B, Gahl B, Häuselmann H, Studer U, Ziswiler H-R, Reichenbach S, Lehmann T. Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res. February 2022;37(2):340-348. |
2 |
1 |
| 2022 |
Everts-Graber J, Burkhard J-P, Schaller B, Reichenbach S, Lehmann T. Reply to potential issues with the use of teriparatide after denosumab-related osteonecrosis of the jaw. J Bone Miner Res. October 2022;37(10):2046-2047. |
0 |
0 |